| |
|
|
|
|
|
 |
| |
|
ÆÄÀÌ·±½ºÄ¸½¶ PILENCE CAPS.[Ethyl Aminobenzoate , Papaverine HCl , Scopolamine HBr]
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
 |
Á¦Ç°º° ÀӺαݱ⠰í½Ã |
|
|
|
1µî±Þ: ¿øÄ¢Àû »ç¿ë±Ý±â / 2µî±Þ: ¸íÈ®ÇÑ ÀÓ»óÀû ±Ù°Å ¶Ç´Â »çÀ¯°¡ ÀÖ´Â °æ¿ì ºÎµæÀÌÇÏ°Ô »ç¿ë / Mµî±Þ: ÀÓ»óÀû»óȲ¿¡ µû¶ó 1µî±Þ ¶Ç´Â 2µî±ÞÀ¸·Î ºÐ·ùµÇ´Â ¼ººÐ
| ¼ººÐ¸í |
¼ººÐÄÚµå |
±Ý±âµî±Þ |
°í½Ã¹øÈ£ |
°í½ÃÀÏÀÚ |
ºñ°í |
| Scopolamine hydrobromide |
D84100ACH |
2 |
20200130 |
20201228 |
žƿ¡ ´ëÇÑ ºÎÀÛ¿ë À§Ç輺. µ¿¹° ½ÇÇè¿¡¼ ±âÇü º¸°í |
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
670301880[A04702621]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ĸ½¶(2006.11.01)(ÇöÀç¾à°¡)
\22 ¿ø/1ĸ½¶(2001.07.13)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»öºÐ¸»ÀÌ µç »ó-û»öÇÏ-¹é»öÀÇ Ä°¼¿Á¦ÀÌ´Ù [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
1000CAPS |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 93.33¹Ð¸®±×·¥ |
1000 ĸ½¶ |
º´ |
8806703018807 |
8806703018838 |
|
| 93.33¹Ð¸®±×·¥ |
100 ĸ½¶ |
PTP |
8806703018807 |
8806703018821 |
|
| 93.33¹Ð¸®±×·¥ |
10 ĸ½¶ |
PTP |
8806703018807 |
8806703018814 |
|
|
| ÁÖ¼ººÐÄÚµå |
D84100ACH
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
À§Åë, º¹Åë, »êÅë, À§»ê°ú´Ù, ¼Ó¾²¸².
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Papaverine][Scopolamine]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:395100ACH ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
Åë»ó ¼ºÀÎ(15¼¼ ÀÌ»ó) 1ȸ 1ݼ¿, 1ÀÏ 3ȸ º¹¿ëÇÑ´Ù.
´Ü, º¹¿ë°£°ÝÀº 4½Ã°£ ÀÌ»óÀ¸·Î ÇÑ´Ù.
|
| ±Ý±â |
1) ³ì³»Àå ȯÀÚ
2) À¯¹®ÇùÂø µî À§Àå°üÀÇ ±â´ÉÀû ÇùÂø ȯÀÚ
3) ¸¶ºñ¼º ÀåÆó»ö ȯÀÚ
4) ÁßÁõ ±Ù¹«·ÂÁõ ȯÀÚ
5) °Å´ë °áÀå ȯÀÚ
6) ºÎÁ¤ ºó¸Æ ȯÀÚ
7) ÁßÁõÀÇ ½ÉÁúȯ ȯÀÚ
8) ÀÌ ¾à¿¡ °ú¹ÎÁõ ȯÀÚ
9) ÃâÇ÷¼º ´ëÀå¿° ȯÀÚ
10) Àü¸³¼º ºñ´ë¿¡ ÀÇÇÑ ¹è´¢Àå¾Ö ȯÀÚ
|
| ½ÅÁßÅõ¿© |
1) ´ÙÀ½ ȯÀÚ¿¡´Â Åõ¿©ÇÏÁö ¾Ê´Â °ÍÀÌ ¿øÄ¢À̳ª ºÎµæÀÌÇÑ °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.: ¼¼±Õ¼º ¼³»ç ȯÀÚ
2) ¿ïÇ÷¼º ½ÉºÎÀü ȯÀÚ
3) ºÎÁ¤¸Æ ȯÀÚ
4) ±Ë¾ç¼º ´ëÀå¿° ȯÀÚ(Áßµ¶¼º °Å´ë°áÀåÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.)
5) °©»ó¼± ±â´É Ç×ÁøÁõ ȯÀÚ
6) °í¿Â ȯ°æ¿¡ Àִ ȯÀÚ
7) Àü¸³¼± ºñ´ë ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
1) ¼ï, ¾Æ³ªÇʶô½Ã¾ç Áõ»ó: ¼ï, ¾Æ³ªÇʶô½Ã½º¾ç Áõ»ó(±¸¿ª, ±¸Åä, ¿ÀÇÑ, ÇǺÎâ¹é, Ç÷¾Ð ÀúÇÏ, È£Èí°ï¶õ, ±â°üÁö ¿¬Ãà, ºÎÁ¾, Ç÷°üºÎÁ¾ µî)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ ½Ç½ÃÇÏ¿© ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â ÀÌ ¾àÀÇ Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ½Ç½ÃÇÑ´Ù.
2) ´«: ¶§¶§·Î »êµ¿, ¸ð¾ç±Ù¸¶ºñ, Á¶ÀýÀå¾Ö µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ¼Òȱâ°è: ±¸°°ÇÁ¶, ±¸°¥, ±¸¿ª, ±¸Åä, º¯ºñ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) ºñ´¢±â°è: ¶§¶§·Î ¹è´¢Àå¾Ö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) Á¤½Å½Å°æ°è: ¶§¶§·Î µÎÅë, µÎÁß°¨ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç °ú·®Åõ¿©½Ã ºÒ¾È, ÈïºÐ, ȯ°¢ ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
6) ¼øÈ¯±â°è: ½É°èÇ×Áø, ºó¸Æ, Ç÷¾ÐÀúÇϰ¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
7) °ú¹ÎÁõ: ¸Å¿ì µå¹°°Ô ÇǺιÝÀÀ, È£Èí°ï¶õÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
8) ±âŸ: ¶§¶§·Î ¾È¸éÈ«Á¶, ¹ßÇÑÀÌ»ó, ÀÌ»ó°í¿ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) Æä³ëÄ¡¾ÆÁø°è ¾à¹°, »ïȯ°è Ç׿ì¿ï¾à, MAO ÀúÇØÁ¦, Ç×È÷½ºÅ¸¹ÎÁ¦, Äû´Ïµò, ¾Æ¸¸Å¸µò, µð¼ÒÇǶó¹Ìµå¿Í º´¿ë½Ã Ç×Äݸ° ÀÛ¿ëÀÌ Áõ°µÉ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù.
2) ¸ÞÅäŬ·ÎÇÁ¶ó¹Ìµå µîÀÇ µµÆÄ¹Î ±æÇ×¾à°ú º´¿ëÅõ¿©½Ã À§Àå°ü¿¡ ´ëÇÑ µÎ ¾à¹°ÀÇ È¿°ú°¡ ¸ðµÎ °¨¾àµÉ ¼ö ÀÖ´Ù.
3) º£Å¸ È¿´É¾à°ú º´¿ë½Ã º£Å¸ È¿´É¾àÀÇ ½É¹ÚÁõ°¡ÀÛ¿ëÀÌ Áõ°µÉ ¼ö ÀÖ´Ù.
|
| Off-label Usage |
[Á¶È¸]
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(papaverine, scopolamine )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Papaverine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Perhaps by its direct vasodilating action on cerebral blood vessels, Papaverine increases cerebral blood flow and decreases cerebral vascular resistance in normal subjects; oxygen consumption is unaltered. These effects may explain the benefit reported from the drug in cerebral vascular encephalopathy.
Scopolamine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Scopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center).
|
| Pharmacology |
Papaverine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries.
Scopolamine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Scopolamine is a muscarinic antagonist structurally similar to the neurotransmitter acetylcholine and acts by blocking the muscarinic acetylcholine receptors and is thus classified as an anticholinergic. Scopolamine has many uses including the prevention of motion sickness. It is not clear how Scopolamine prevents nausea and vomiting due to motion sickness. The vestibular part of the ear is very important for balance. When a person becomes disoriented due to motion, the vestibule sends a signal through nerves to the vomiting center in the brain, and vomiting occurs. Acetylcholine is a chemical that nerves use to transmit messages to each other. It is believe that Scopolamine prevents communication between the nerves of the vestibule and the vomiting center in the brain by blocking the action of acetylcholine. Scopolamine also may work directly on the vomiting center. Scopolamine must be taken before the onset of motion sickness to be effective.
|
| Metabolism |
Papaverine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Xanthine dehydrogenase/oxidase
Scopolamine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Papaverine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ ~90%
Scopolamine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Papaverine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 0.5-2 hours
Scopolamine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Papaverine¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
Scopolamine¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
Scopolamine HBrÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- È¿°ú¹ßÇö½Ã°£
- °æ±¸, ±ÙÀ°ÁÖ»ç : 0.5-1 ½Ã°£
- Á¤¸ÆÁÖ»ç : 10 ºÐ
- È¿°úÁö¼Ó½Ã°£
- °æ±¸, ±ÙÀ°ÁÖ»ç : 4-6 ½Ã°£
- Á¤¸ÆÁÖ»ç : 2 ½Ã°£
- ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£ : 20-60 ºÐ. Á¤»óÀ¸·Î ¿ÏÀüÈ÷ ȸº¹µÇ´Â µ¥¿¡´Â 3-7ÀÏÀÌ °É¸± ¼ö ÀÖ´Ù.
- Èí¼ö : ¸ðµç Åõ¿©°æ·Î·Î Àß Èí¼öµÈ´Ù.
- ´Ü¹é°áÇÕ : Ç÷Àå´Ü¹é°ú °¡¿ªÀû °áÇÕ
- ´ë»ç : °£´ë»ç
- ¼Ò½Ç : ½Å¹è¼³
Papaverine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : °æ±¸ : ½Å¼Ó
- ´Ü¹é°áÇÕ : 90%
- ´ë»ç : °£¿¡¼ ½Å¼ÓÈ÷ ´ë»ç
- ¹Ý°¨±â : 0.5-1.5½Ã°£
- ¼Ò½Ç : ´¢¸¦ ÅëÇØ ÁÖ·Î ´ë»çü·Î ¹è¼³
Ethyl AminobenzoateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : °æ±¸ : À§Àå°ü¿¡¼ Èí¼öµÈ´Ù.
- ºÐÆ÷ : ºÐÆ÷¿ëÀû : Á¤¸ÆÁÖ»ç : ½Å»ý¾Æ : 0.086-0.244 L/kg
- ´ë»ç : Glycine¿¡ Æ÷ÇյǾî hippuric acid·Î ÀüȯµÈ´Ù.
- ¹Ý°¨±â : ½Å»ý¾Æ : 0.75-7.4 ½Ã°£
- ¼Ò½Ç : ´ë»çü·Î ½Å¹è¼³µÈ´Ù.
|
| Biotransformation |
Papaverine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
Scopolamine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Papaverine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
Scopolamine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Papaverine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Probenecid Probenecid increases the antibiotic's level
Scopolamine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Papaverine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
|
| Drug Target |
[Drug Target]
|
| Description |
Papaverine¿¡ ´ëÇÑ Description Á¤º¸ An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. [PubChem]
Scopolamine¿¡ ´ëÇÑ Description Á¤º¸ An alkaloid from Solanaceae, especially Datura metel L. and Scopola carniolica. Scopolamine and its quaternary derivatives act as antimuscarinics like atropine, but may have more central nervous system effects. Among the many uses are as an anesthetic premedication, in urinary incontinence, in motion sickness, as an antispasmodic, and as a mydriatic and cycloplegic. [PubChem]
|
| Dosage Form |
Papaverine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid Intravenous
Scopolamine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Disc TransdermalLiquid IntravenousSolution IntramuscularSolution IntravenousTablet Oral
|
| Drug Category |
Papaverine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Phosphodiesterase InhibitorsVasodilator Agents
Scopolamine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AdjuvantsAdjuvants, AnesthesiaAntimuscarinicsAntispasmodicsCholinergic AntagonistsMuscarinic AntagonistsMydriatics
|
| Smiles String Canonical |
Papaverine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
Scopolamine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN1C2CC(CC1C1OC21)OC(=O)C(CO)C1=CC=CC=C1
|
| Smiles String Isomeric |
Papaverine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
Scopolamine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)C1=CC=CC=C1
|
| InChI Identifier |
Papaverine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3
Scopolamine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3
|
| Chemical IUPAC Name |
Papaverine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
Scopolamine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ Not Available
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-10-13
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|